BioMark Diagnostics Inc. (BUX.CN)
CAD 0.25
(-1.96%)
CAD 0.25
(-1.96%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.11 Million CAD | -5.03% |
| 2022 | -1.34 Million CAD | -10.0% |
| 2021 | -1.22 Million CAD | -13.3% |
| 2020 | -1.07 Million CAD | 9.31% |
| 2019 | -1.2 Million CAD | -118.25% |
| 2018 | -18.75 Thousand CAD | 24.92% |
| 2017 | -66.18 Thousand CAD | -0.02% |
| 2016 | -25.53 Thousand CAD | 48.54% |
| 2015 | -1.4 Million CAD | 51.2% |
| 2014 | -2.87 Million CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -546.54 Thousand CAD | -125.33% |
| 2023 FY | - CAD | -5.03% |
| 2023 Q2 | -295.73 Thousand CAD | -1.71% |
| 2023 Q1 | -290.77 Thousand CAD | 21.21% |
| 2023 Q3 | -341.5 Thousand CAD | -15.47% |
| 2023 Q4 | -396.39 Thousand CAD | -16.07% |
| 2022 Q1 | -294.28 Thousand CAD | 47.7% |
| 2022 FY | - CAD | -10.0% |
| 2022 Q4 | -369.07 Thousand CAD | -31.26% |
| 2022 Q3 | -281.16 Thousand CAD | 29.93% |
| 2022 Q2 | -401.27 Thousand CAD | -36.35% |
| 2021 Q2 | -175.33 Thousand CAD | 38.05% |
| 2021 FY | - CAD | -13.3% |
| 2021 Q4 | -562.69 Thousand CAD | -177.99% |
| 2021 Q3 | -202.41 Thousand CAD | -15.44% |
| 2021 Q1 | -283.03 Thousand CAD | 49.49% |
| 2020 FY | - CAD | 9.31% |
| 2020 Q4 | -560.4 Thousand CAD | -190.07% |
| 2020 Q2 | -184.47 Thousand CAD | -41.01% |
| 2020 Q3 | -193.19 Thousand CAD | -4.73% |
| 2020 Q1 | -130.82 Thousand CAD | 53.22% |
| 2019 Q3 | -672.89 Thousand CAD | -395.04% |
| 2019 Q4 | -279.67 Thousand CAD | 58.44% |
| 2019 FY | - CAD | -118.25% |
| 2019 Q1 | -120.55 Thousand CAD | 2.16% |
| 2019 Q2 | -135.92 Thousand CAD | -12.75% |
| 2018 FY | - CAD | 24.92% |
| 2018 Q4 | -123.21 Thousand CAD | 26.95% |
| 2018 Q3 | -168.66 Thousand CAD | -5.05% |
| 2018 Q1 | -110.91 Thousand CAD | 21.83% |
| 2018 Q2 | -160.55 Thousand CAD | -44.76% |
| 2017 Q3 | -176.37 Thousand CAD | 19.25% |
| 2017 FY | - CAD | -0.02% |
| 2017 Q1 | -195.72 Thousand CAD | 19.59% |
| 2017 Q2 | -218.42 Thousand CAD | -11.6% |
| 2017 Q4 | -141.88 Thousand CAD | 19.56% |
| 2016 Q1 | -215.53 Thousand CAD | 69.43% |
| 2016 FY | - CAD | 48.54% |
| 2016 Q4 | -243.4 Thousand CAD | -117.8% |
| 2016 Q3 | -111.75 Thousand CAD | 25.65% |
| 2016 Q2 | -150.3 Thousand CAD | 30.26% |
| 2015 FY | - CAD | 51.2% |
| 2015 Q1 | -209.29 Thousand CAD | 70.74% |
| 2015 Q3 | -260.89 Thousand CAD | -12.36% |
| 2015 Q4 | -705.15 Thousand CAD | -170.29% |
| 2015 Q2 | -232.18 Thousand CAD | -10.94% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q3 | -2.05 Million CAD | -3889.1% |
| 2014 Q4 | -715.31 Thousand CAD | 65.12% |
| 2014 Q2 | -51.4 Thousand CAD | 22.11% |
| 2014 Q1 | -65.99 Thousand CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Izotropic Corporation | -1.6 Million CAD | 30.586% |
| Sona Nanotech Inc. | -2.01 Million CAD | 44.809% |